Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies for patients with cancer and other incurable diseases. Its lead product candidate, anitocabtagene autoleuce... Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies for patients with cancer and other incurable diseases. Its lead product candidate, anitocabtagene autoleucel (anito-cel), utilizes the proprietary ddCAR platform and is in phase 3 clinical trials for relapsed or refractory multiple myeloma, featuring D-Domain technology for enhanced control and safety. The company advances ACLX-001, targeting BCMA in phase 1 for the same indication via the ARC-SparX platform, and ACLX-002 in phase 1 against CD123 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Preclinical efforts include ACLX-003 for AML and MDS, alongside programs for solid tumors. Arcellx maintains a strategic collaboration with Kite Pharma, a Gilead company, to co-develop and co-commercialize anito-cel. Founded in 2014 and headquartered in Redwood City, California, Arcellx focuses on engineering safer, more effective, and accessible immunotherapies to transform cancer treatment.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Arcellx is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Arcellx is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Arcellx's data?

Start your 30-day free trial to request a data review for Arcellx.

Start Free Trial

Legal Center Contact Us

Arcellx Inc

Arcellx is not subject to EU Taxonomy reporting

Account Restricted